Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally
Go back to Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 4.21 -0.04 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.25 | 52 Week High | $2.43 | |||
| Open | $4.19 | 52 Week Low | $1.05 | |||
| Day High | $4.41 | P/E | N/A | |||
| Day Low | $4.15 | EPS | $-1.79 | |||
| Volume | 2,542,017 | |||||
